Ascension Seton Medical Center
- Type
- Teaching hospital
- Where
- Austin, TX
- Medicare CCN
- 450056
- Received
- $2,137,535 in 395 records, 2025 ($140,314 general, $1,997,220 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ASCENSION SETON MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 31 | $140,314 |
| 2025 | Research payment | 364 | $1,997,220 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 364 | $1,997,220 |
| Long term medical supply or device loan | 5 | $54,000 |
| Debt forgiveness | 19 | $46,410 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $33,600 |
| Grant | 1 | $5,000 |
| Space rental or facility fees (teaching hospital only) | 1 | $684 |
| Food and Beverage | 3 | $350 |
| Gift | 1 | $268 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, CV | 2025 | |
| 2025-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $12,879 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2025 |
| 2025-12-31 | Stryker Corporation | $5,650 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $4,740 | Long term medical supply or device loan | In-kind items and services | Bone Mill Plus Device, INSTRUMENTS | 2025 | |
| 2025-12-24 | Janssen Research & Development, LLC | $14,290 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-24 | Boston Scientific Corporation | $5,000 | Grant | Cash or cash equivalent | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-24 | Janssen Research & Development, LLC | $93 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-12-24 | Abbott Laboratories | $90 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-12-23 | Medtronic, Inc. | $2,620 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-12-20 | BIOTRONIK INC. | $477 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-48 | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | $19,758 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-19 | Janssen Research & Development, LLC | $1,088 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-12-19 | Abbott Laboratories | $39 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-12-18 | Surmodics, Inc. | $7,279 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $3,138 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-48 | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $1,387 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-48 | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-12-18 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-12-17 | Janssen Research & Development, LLC | $8,802 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-17 | United Therapeutics Corporation | $4,719 | Research payment | Cash or cash equivalent | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2025 | |
| 2025-12-15 | United Therapeutics Corporation | $4,116 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-12-15 | Janssen Research & Development, LLC | $2,720 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-12-12 | Janssen Research & Development, LLC | $9,098 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-12-12 | Medtronic, Inc. | $5,175 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | $3,105 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-12-11 | Edwards Lifesciences Corporation | $20,094 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-12-11 | Medtronic, Inc. | $978 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-12-05 | Edwards Lifesciences Corporation | $55,155 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | $1,900 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-12-03 | Janssen Research & Development, LLC | $112 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-12-01 | Humacyte Global, Inc. | $3,834 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-12-01 | Humacyte Global, Inc. | $1,099 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-12-01 | Janssen Research & Development, LLC | $776 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-11-26 | Medtronic, Inc. | $640 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-11-26 | Abbott Laboratories | $455 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-11-25 | GLOBAL BLOOD THERAPEUTICS, INC. | $4,500 | Research payment | Cash or cash equivalent | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2025 | |
| 2025-11-24 | Abbott Laboratories | $2,311 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-11-24 | Medtronic, Inc. | $100 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-11-24 | Medtronic, Inc. | $40 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-11-21 | Janssen Research & Development, LLC | $4,880 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-11-21 | United Therapeutics Corporation | $600 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-11-20 | United Therapeutics Corporation | $914 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-11-19 | Janssen Research & Development, LLC | $8,285 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-11-19 | Janssen Research & Development, LLC | $2,404 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-11-18 | Cochlear Americas | $82 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-11-17 | Janssen Research & Development, LLC | $2,448 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-11-17 | Janssen Research & Development, LLC | $223 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-11-14 | Janssen Research & Development, LLC | $26,451 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-11-14 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-11-13 | Janssen Research & Development, LLC | $1,032 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-11-12 | Humacyte Global, Inc. | $1,500 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-11-12 | Humacyte Global, Inc. | $1,500 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-11-12 | Humacyte Global, Inc. | $150 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-11-07 | Janssen Research & Development, LLC | $11,600 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-11-07 | Janssen Research & Development, LLC | $7,479 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-11-07 | Regeneron Pharmaceuticals, Inc. | $3,942 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-11-07 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-11-03 | Abbott Laboratories | $13,672 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-10-28 | Medtronic, Inc. | $4,925 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-10-28 | Abbott Laboratories | $1,200 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Cardiac Rhythm Management | NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Hea | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | $3,830 | Research payment | Cash or cash equivalent | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial | 2025 | |
| 2025-10-27 | Abbott Laboratories | $3,519 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Cardiac Rhythm Management | NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Hea | 2025 |
| 2025-10-27 | Abbott Laboratories | $2,139 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Cardiac Rhythm Management | NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Hea | 2025 |
| 2025-10-23 | Regeneron Pharmaceuticals, Inc. | $2,334 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-10-22 | Surmodics, Inc. | $21,361 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Surmodics, Inc. | $15,962 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Surmodics, Inc. | $4,250 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Janssen Research & Development, LLC | $1,656 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-10-22 | Surmodics, Inc. | $600 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Surmodics, Inc. | $300 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Surmodics, Inc. | $300 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-22 | Surmodics, Inc. | $300 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-10-20 | Janssen Research & Development, LLC | $26,689 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-17 | Janssen Research & Development, LLC | $1,032 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-10-17 | Janssen Research & Development, LLC | $87 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-10-16 | United Therapeutics Corporation | $914 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-16 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-10-16 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-10-16 | Edwards Lifesciences Corporation | $120 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $203 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-15 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2025 |
| 2025-10-10 | Edwards Lifesciences Corporation | $55,803 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-10-09 | Edwards Lifesciences Corporation | $97,802 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-10-09 | Janssen Research & Development, LLC | $1,668 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-09 | Janssen Research & Development, LLC | $547 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-10-08 | Humacyte Global, Inc. | $1,430 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-10-06 | Janssen Research & Development, LLC | $1,094 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $21,500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,342 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | $2,216 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-10-02 | Janssen Research & Development, LLC | $3,746 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-02 | CSL Behring | $300 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-09-25 | Janssen Research & Development, LLC | $792 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-24 | Janssen Research & Development, LLC | $17,364 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-24 | Janssen Research & Development, LLC | $3,807 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-24 | Edwards Lifesciences Corporation | $2,500 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-09-24 | Edwards Lifesciences Corporation | $1,250 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-09-24 | Edwards Lifesciences Corporation | $120 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-09-24 | Janssen Research & Development, LLC | $62 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-09-22 | United Therapeutics Corporation | $4,991 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-09-22 | Janssen Research & Development, LLC | $239 | Research payment | Cash or cash equivalent | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial | 2025 | |
| 2025-09-22 | Janssen Research & Development, LLC | $230 | Research payment | Cash or cash equivalent | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $23,856 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $11,128 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $11,091 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $8,724 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $828 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-09-19 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-09-19 | Edwards Lifesciences Corporation | $607 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-09-19 | Medtronic, Inc. | $20 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-09-17 | Bolton Medical Inc | $1,500 | Research payment | Cash or cash equivalent | THORAFLEX HYBRID Device, ENDOVASCULAR AORTIC REPAIR | EXTEND | 2025 |
| 2025-09-15 | Impulse Dynamics (USA) Inc. | $207 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
| 2025-09-12 | Janssen Research & Development, LLC | $56 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-10 | Janssen Research & Development, LLC | $547 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-09-05 | Janssen Research & Development, LLC | $1,516 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-09-03 | United Therapeutics Corporation | $4,050 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-08-31 | Merck Sharp & Dohme LLC | $637 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2025 |
| 2025-08-27 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | A PHASE 12 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BOSUTINIB IN PEDIATRIC PATIENTS WITH CML WHO ARE RESISTA | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | $26,092 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-08-25 | Janssen Research & Development, LLC | $7,939 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-08-25 | Janssen Research & Development, LLC | $3,851 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-08-25 | Humacyte Global, Inc. | $1,500 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $1,500 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $1,139 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $1,083 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $150 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $138 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $138 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-08-22 | United Therapeutics Corporation | $3,275 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-08-22 | Janssen Research & Development, LLC | $1,094 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-08-21 | Janssen Research & Development, LLC | $1,032 | Research payment | Cash or cash equivalent | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial | 2025 | |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | $316 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-08-20 | Janssen Research & Development, LLC | $15,837 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $7,872 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, MIDFACE, VOLUMETRIC, 00084, LP, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $4,532 | Debt forgiveness | Cash or cash equivalent | IPS, SPLINT, PALATAL, LP, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $2,736 | Debt forgiveness | Cash or cash equivalent | IPS, CUTTING GUIDE, ORTHOG, COMPLEX, 00163, LP, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $1,661 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, MIDFACE/ORTHOG, 00069, LP, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $1,661 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, MAND/ORTHOG, 00067, LP, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $1,328 | Debt forgiveness | Cash or cash equivalent | IPS, SPLINT, ORTHOG, DOUBLE JAW, SET, LP, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $902 | Debt forgiveness | Cash or cash equivalent | IPS, SUPPLEMENTAL MODEL, HALF, 00006, LP, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | KLS-Martin L.P. | $902 | Debt forgiveness | Cash or cash equivalent | IPS, SUPPLEMENTAL MODEL, HALF, 00006, LP, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-08-20 | Bolton Medical Inc | $828 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TIGER PAS | 2025 |
| 2025-08-18 | Abbott Laboratories | $9,452 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-08-14 | Impulse Dynamics (USA) Inc. | $1,293 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
| 2025-08-13 | Janssen Research & Development, LLC | $1,032 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-08-13 | United Therapeutics Corporation | $914 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-08-13 | Janssen Research & Development, LLC | $180 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-08-11 | CSL Behring | $3,750 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-08-11 | Abbott Laboratories | $3,067 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-08-11 | CSL Behring | $2,400 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-08-11 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-08-07 | Regeneron Pharmaceuticals, Inc. | $2,899 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-08-04 | Abbott Laboratories | $30,285 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-08-01 | GLOBAL BLOOD THERAPEUTICS, INC. | $5,100 | Research payment | Cash or cash equivalent | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2025 | |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | $3,110 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-07-30 | Bolton Medical Inc | $828 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TIGER PAS | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $21,840 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-07-25 | Janssen Research & Development, LLC | $4,700 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-07-25 | Janssen Research & Development, LLC | $148 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-07-23 | Janssen Research & Development, LLC | $9,405 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-07-23 | Janssen Research & Development, LLC | $7,049 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-07-23 | Janssen Research & Development, LLC | $4,285 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-07-23 | Janssen Research & Development, LLC | $2,619 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 | |
| 2025-07-23 | Bolton Medical Inc | $1,338 | Research payment | Cash or cash equivalent | THORAFLEX HYBRID Device, ENDOVASCULAR AORTIC REPAIR | EXTEND | 2025 |
| 2025-07-23 | Bolton Medical Inc | $828 | Research payment | Cash or cash equivalent | RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | TIGER PAS | 2025 |
| 2025-07-23 | NeuroLogica Corporation, a Samsung Company | $116 | Food and Beverage | Cash or cash equivalent | V8 Device, UltraSound | 2025 | |
| 2025-07-23 | NeuroLogica Corporation, a Samsung Company | $116 | Food and Beverage | Cash or cash equivalent | V8 Device, UltraSound | 2025 | |
| 2025-07-23 | NeuroLogica Corporation, a Samsung Company | $116 | Food and Beverage | Cash or cash equivalent | V8 Device, UltraSound | 2025 | |
| 2025-07-22 | Regeneron Pharmaceuticals, Inc. | $1,338 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-07-18 | Humacyte Global, Inc. | $500 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-07-18 | Humacyte Global, Inc. | $150 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-07-17 | Regeneron Pharmaceuticals, Inc. | $316 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-07-16 | Medtronic, Inc. | $8,498 | Research payment | Cash or cash equivalent | ENDURANT IIS Device, Aortic Stent Grafts | PSR-APV | 2025 |
| 2025-07-16 | Penumbra, Inc. | $650 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STORM-PE | 2025 |
| 2025-07-16 | Bolton Medical Inc | $150 | Research payment | Cash or cash equivalent | THORAFLEX HYBRID Device, ENDOVASCULAR AORTIC REPAIR | EXTEND | 2025 |
| 2025-07-15 | Impulse Dynamics (USA) Inc. | $1,800 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
| 2025-07-15 | Impulse Dynamics (USA) Inc. | $207 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
| 2025-07-15 | Impulse Dynamics (USA) Inc. | $56 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
| 2025-07-14 | Medtronic, Inc. | $7,162 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-07-11 | Janssen Research & Development, LLC | $2,064 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and | 2025 | |
| 2025-07-07 | Edwards Lifesciences Corporation | $48,980 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-07-07 | Edwards Lifesciences Corporation | $9,084 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $4,434 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-07-04 | Regeneron Pharmaceuticals, Inc. | $1,477 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-07-01 | Merck Sharp & Dohme LLC | $30,725 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2025 |
| 2025-07-01 | Impulse Dynamics (USA) Inc. | $1,713 | Research payment | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2025 |
The latest 200 records of 395.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Austin, TX, county Travis County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Austin, TX | County Travis County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 979,539 | 1,330,015 | 30,188,424 |
| Population, 2020 census P1 | 961,855 | 1,290,188 | 29,145,505 |
| Median age B01002 | 34.7 | 35.6 | 35.6 |
| Under 18 B01001 | 18.0% | 20.2% | 25.0% |
| 65 and over B01001 | 10.4% | 11.0% | 13.4% |
| Households B11001 | 456,113 | 583,747 | 10,992,816 |
| Foreign born B05002 | 18.7% | 18.1% | 17.6% |
| Median household income B19013 | $93,658 | $99,611 | $78,476 |
| Median family income B19113 | $128,808 | $131,256 | $94,599 |
| Per capita income B19301 | $62,862 | $62,607 | $40,752 |
| Poverty rate B17001 | 12.0% | 10.9% | 13.8% |
| Unemployment rate B23025 | 4.7% | 4.6% | 5.3% |
| Civilian labor force B23025 | 617,774 | 799,524 | 15,233,563 |
| Mean commute (minutes) B08013 | 23.7 | 25.2 | 26.7 |
| Bachelor's degree or higher B15003 | 59.6% | 56.6% | 33.8% |
| Housing units B25001 | 483,071 | 618,236 | 12,128,515 |
| Owner-occupied B25003 | 43.4% | 52.1% | 62.6% |
| Renters B25003 | 56.6% | 47.9% | 37.4% |
| Median home value B25077 | $555,300 | $523,000 | $283,800 |
| Median gross rent B25064 | $1,729 | $1,744 | $1,403 |
| White, not Hispanic B03002 | 47.0% | 46.9% | 39.1% |
| Black B03002 | 7.3% | 7.8% | 11.9% |
| Hispanic or Latino B03002 | 31.9% | 32.6% | 39.7% |
| Asian B03002 | 9.0% | 7.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Austin, TX.
Comments